QUALITATIVE AND QUANTITATIVE COMPOSITION
Interferon beta-1a injection, for intramuscular use single-use prefilled autoinjector pen.
- Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three-years without evidence of continuous progression between relapses; AVONEX slows the progression of disability and decreases the frequency of relapses.
- Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
Single-use prefilled autoinjector containing 0.5 mL solution with 30 mcg.
Recommended dose is 30 micrograms once a week.
MARKETING AUTHORIZATION HOLDER